Ocugen reports Q2 net loss $0.04/sh; advances OCU400 Phase 3 trial, raises $32.6M

Ocugen, Inc.

2024-Q2 EPS reported -$0.09 revenue$2,155,000

Net loss per share $0.04 in Q2 2024 versus $0.10 in Q2 2023; total operating expenses $16.6M, down from $24.0M.
Cash, equivalents, restricted cash $16.0M at June 30, 2024, down from $39.5M at Dec 31, 2023.
Subsequent to quarter end, closed public offering with net proceeds $32.6M, extending cash runway into Q3 2025.
Actively dosing patients in OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa; FDA approved expanded access program.
OCU410 Phase 2 initiated for geographic atrophy; OCU410ST high-dose dosing; OCU200 clinical hold discussions ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.